Rheumatoid arthritis - Life Sciences bibliographies - in Harvard style

In-text: (Burch and Onysko, 2015)

Your Bibliography: Burch, J. and Onysko, M., 2015. Current standards and future treatments of rheumatoid arthritis. [online] Formulary Journal. Available at: <http://formularyjournal.modernmedicine.com/formulary-journal/news/clinical/clinical-pharmacology/current-standards-and-future-treatments-rheuma?page=full> [Accessed 22 February 2015].

In-text: (Burmester et al., 2013)

Your Bibliography: Burmester, G., Blanco, R., Charles-Schoeman, C., Wollenhaupt, J., Zerbini, C., Benda, B., Gruben, D., Wallenstein, G., Krishnaswami, S., Zwillich, S., Koncz, T., Soma, K., Bradley, J. and Mebus, C., 2013. Tofacitinib (CP-690,550) in combination with methotrexate in patients with active rheumatoid arthritis with an inadequate response to tumour necrosis factor inhibitors: a randomised phase 3 trial. The Lancet, 381(9865), pp.451-460.

In-text: (Colmegna, Ohata and Menard, 2012)

Your Bibliography: Colmegna, I., Ohata, B. and Menard, H., 2012. Current Understanding of Rheumatoid Arthritis Therapy. Clin Pharmacol Ther, 91(4), pp.607-620.

In-text: (Fleischmann et al., 2012)

Your Bibliography: Fleischmann, R., Kremer, J., Cush, J., Schulze-Koops, H., Connell, C., Bradley, J., Gruben, D., Wallenstein, G., Zwillich, S. and Kanik, K., 2012. Placebo-Controlled Trial of Tofacitinib Monotherapy in Rheumatoid Arthritis. New England Journal of Medicine, 367(6), pp.495-507.

In-text: (Genovese et al., 2014)

Your Bibliography: Genovese, M., van der Heijde, D., Keystone, E., Spindler, A., Benhamou, C., Kavanaugh, A., Fudman, E., Lampl, K., O'Brien, C., Duffield, E., Poiley, J. and Weinblatt, M., 2014. A Phase III, Multicenter, Randomized, Double-blind, Placebo-controlled, Parallel-group Study of 2 Dosing Regimens of Fostamatinib in Patients with Rheumatoid Arthritis with an Inadequate Response to a Tumor Necrosis Factor-  Antagonist. The Journal of Rheumatology, 41(11), pp.2120-2128.

In-text: (Lee et al., 2014)

Your Bibliography: Lee, E., Fleischmann, R., Hall, S., Wilkinson, B., Bradley, J., Gruben, D., Koncz, T., Krishnaswami, S., Wallenstein, G., Zang, C., Zwillich, S. and van Vollenhoven, R., 2014. Tofacitinib versus Methotrexate in Rheumatoid Arthritis. New England Journal of Medicine, 370(25), pp.2377-2386.

In-text: (Lee et al., 2014)

Your Bibliography: Lee, E., Fleischmann, R., Hall, S., Wilkinson, B., Bradley, J., Gruben, D., Koncz, T., Krishnaswami, S., Wallenstein, G., Zang, C., Zwillich, S. and van Vollenhoven, R., 2014. Tofacitinib versus Methotrexate in Rheumatoid Arthritis. New England Journal of Medicine, 370(25), pp.2377-2386.

In-text: (Renoux, Dell’Aniello, Garbe and Suissa, 2008)

Your Bibliography: Renoux, C., Dell’Aniello, S., Garbe, E. and Suissa, S., 2008. Hormone replacement therapy use and the risk of stroke. Maturitas, 61(4), pp.305-309.

In-text: (Renoux, Dell’Aniello, Garbe and Suissa, 2008)

Your Bibliography: Renoux, C., Dell’Aniello, S., Garbe, E. and Suissa, S., 2008. Hormone replacement therapy use and the risk of stroke. Maturitas, 61(4), pp.305-309.

In-text: (Renoux, Dell’Aniello, Garbe and Suissa, 2008)

Your Bibliography: Renoux, C., Dell’Aniello, S., Garbe, E. and Suissa, S., 2008. Hormone replacement therapy use and the risk of stroke. Maturitas, 61(4), pp.305-309.

In-text: (Renoux, Dell’Aniello, Garbe and Suissa, 2008)

Your Bibliography: Renoux, C., Dell’Aniello, S., Garbe, E. and Suissa, S., 2008. Hormone replacement therapy use and the risk of stroke. Maturitas, 61(4), pp.305-309.

In-text: (Renoux, Dell’Aniello, Garbe and Suissa, 2008)

Your Bibliography: Renoux, C., Dell’Aniello, S., Garbe, E. and Suissa, S., 2008. Hormone replacement therapy use and the risk of stroke. Maturitas, 61(4), pp.305-309.

In-text: (Taylor et al., 2011)

Your Bibliography: Taylor, P., Quattrocchi, E., Mallett, S., Kurrasch, R., Petersen, J. and Chang, D., 2011. Ofatumumab, a fully human anti-CD20 monoclonal antibody, in biological-naive, rheumatoid arthritis patients with an inadequate response to methotrexate: a randomised, double-blind, placebo-controlled clinical trial. Annals of the Rheumatic Diseases, 70(12), pp.2119-2125.

In-text: (van Vollenhoven et al., 2012)

Your Bibliography: van Vollenhoven, R., Fleischmann, R., Cohen, S., Lee, E., García Meijide, J., Wagner, S., Forejtova, S., Zwillich, S., Gruben, D., Koncz, T., Wallenstein, G., Krishnaswami, S., Bradley, J. and Wilkinson, B., 2012. Tofacitinib or Adalimumab versus Placebo in Rheumatoid Arthritis. New England Journal of Medicine, 367(6), pp.508-519.

In-text: (Weinblatt et al., 2014)

Your Bibliography: Weinblatt, M., Genovese, M., Ho, M., Hollis, S., Rosiak-Jedrychowicz, K., Kavanaugh, A., Millson, D., Leon, G., Wang, M. and van der Heijde, D., 2014. Effects of fostamatinib, an oral spleen tyrosine kinase inhibitor, in rheumatoid arthritis patients with an inadequate response to methotrexate: Results from a phase III, multicenter, randomized, double-blind, placebo-controlled, parallel-group study. Arthritis & Rheumatology, p.n/a-n/a.